Results 11 to 20 of about 47,533 (300)

Multi-Pathway Study for Oxaliplatin Resistance Reduction [PDF]

Current Issues in Molecular Biology
Chemotherapy for cancer frequently uses platinum-based medications, including oxaliplatin, carboplatin, and cisplatin; however, due to their high systemic toxicity, lack of selectivity, drug resistance, and other side effects, platinum-based medications ...
Tong Ye, Chen Wu, Jintong Na, Xiyu Liu, Yong Huang   +4 more
doaj   +4 more sources

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2 [PDF]

Molecular Therapy: Oncolytics, 2021
Although oxaliplatin is an effective chemotherapeutic drug commonly used for colorectal cancer (CRC) treatment, drug resistance usually occurs during the long-term use of it.
Wei Sun, Yang Ge, Junpeng Cui, Yifan Yu, Baolin Liu   +4 more
doaj   +3 more sources

MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer

Frontiers in Oncology, 2021
Colorectal cancer is one of the most common malignancies worldwide. Oxaliplatin is the first-line chemotherapeutic agent for the treatment of advanced colorectal cancer. However, acquired resistance to oxaliplatin limits its therapeutic efficacy, and the
Xiao-Lan Qian, Fang Zhou, Song Xu, Jian Jiang, Zhi-Peng Chen, Shao-Kai Wang, Yun Zuo, Chen Ni   +7 more
doaj   +3 more sources

Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer

Advanced Science, 2023
Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer (CRC); however, frequent drug resistance limits its therapeutic efficacy in patients.
Kaixuan Zeng, Weihao Li, Yue Wang, Zifei Zhang, Linjie Zhang, Weili Zhang, Yue Xing, Chi Zhou   +7 more
doaj   +2 more sources

Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis [PDF]

Molecular Medicine
Background Chemotherapy resistance is a major challenge in the treatment of intermediate and advanced gastric cancer (GC). This study aimed to recognize oxaliplatin resistance-related genes (OXARGs) in GC and to explore their role and mechanism in ...
Yan Zhang, Jian Cao, Zheng Yuan, Jiahui Zhou, Hao Zuo, Xinsheng Miao, Xinhua Gu   +6 more
doaj   +2 more sources

LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer

Molecular Therapy: Nucleic Acids, 2020
Oxaliplatin resistance is a major challenge in the clinical treatment for advanced colorectal cancer (CRC). Long non-coding RNAs (lncRNAs) are involved in tumorigenesis and progression as critical regulators, while their potential roles in ...
Xiangfeng Meng, Wu Sun, Jing Yu, Yu Zhou, Yuanyuan Gu, Jiayi Han, Likun Zhou, Xiaohong Jiang, Chen Wang   +8 more
doaj   +3 more sources

Correction: An integrative analysis of transcriptome, methylome and single-cell RNA sequencing data identifies UBE2H as a marker of oxaliplatin resistance in colorectal cancer. [PDF]

Cancer Cell Int
Fang J, Zhu Q, Hong B, Li X, Wang H.
europepmc   +3 more sources

THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer [PDF]

Molecular Cancer
Cancer-associated fibroblasts (CAFs) exert multiple tumor-promoting functions and are key contributors to drug resistance. The mechanisms by which specific subsets of CAFs facilitate oxaliplatin resistance in colorectal cancer (CRC) have not been fully ...
Xing Zhou, Jiashu Han, Anning Zuo, Yuhao Ba, Shutong Liu, Hui Xu, Yuyuan Zhang, Siyuan Weng, Zhaokai Zhou, Long Liu, Peng Luo, Quan Cheng, Chuhan Zhang, Yukang Chen, Dan Shan, Benyu Liu, Shuaixi Yang, Xinwei Han, Jinhai Deng, Zaoqu Liu   +19 more
doaj   +2 more sources

Targeting the ARL4C/RAP1/PI3K-Akt-mTOR signaling loop promotes ARL4C ubiquitination and reverses oxaliplatin resistance in colorectal cancer. [PDF]

Theranostics
Wang Y, Chang Z, Sun Z, Wang L, Li J, Li G, Wang Y, Zhang J, Ai L, Zhang Z, Dong J, Liu M.   +11 more
europepmc   +3 more sources

Phosphorylation of KIAA1429 promotes oxaliplatin resistance through activating the FZD7-Wnt signaling in BRAFV600E-mutated colorectal cancer [PDF]

Journal of Experimental & Clinical Cancer Research
Background The current standard therapeutic approach for colorectal cancer (CRC) is surgical operation and oxaliplatin (OXA)-based neoadjuvant chemotherapy.
Taixuan Wan, Minyi He, Zhanzhen Liu, Yihang Zhou, Yebohao Zhou, Wei Xiao, Hao Xie, Shuangling Luo, Haoqi Zheng, Liang Kang, Yunxing Shi, Liang Huang   +11 more
doaj   +2 more sources